Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany
Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany.
Europace. 2015 Aug;17(8):1300-8. doi: 10.1093/europace/euu393. Epub 2015 Feb 20.
Interaction between dronedarone and digitalis has been discussed as a possible cause for increased mortality in the presence of dronedarone observed in the PALLAS trial. The aim of this study was to assess possible proarrhythmic effects of dronedarone in combination with digitalis in an experimental whole heart model.
Twenty-six female rabbits underwent chronic oral treatment with dronedarone (50 mg/kg/day for 6 weeks). Twenty-four rabbits received placebo. Heart failure was induced by rapid ventricular pacing. Sham-operated rabbits received a right-ventricular pacing lead but were not paced. Thereafter, hearts were isolated and Langendorff-perfused. Monophasic action potentials and a 12 lead electrocardiogram showed a dose-dependent decrease of QT interval, APD90, effective refractory periods, and postrepolarization refractoriness in control hearts and dronedarone-pretreated hearts after application of ouabain (0.1 and 0.2 µM). After acute application of ouabain, ventricular fibrillation (VF) was inducible by programmed ventricular stimulation in 6 of 12 untreated sham hearts (38 episodes) as compared with 7 of 11 dronedarone-pretreated sham hearts (76 episodes). In untreated failing hearts, 6 of 12 hearts were inducible (47 episodes) as compared with 7 of 15 hearts dronedarone-pretreated failing hearts (93 episodes).
In this study, ouabain treatment resulted in an increased ventricular vulnerability in chronically dronedarone-pretreated control and failing hearts. Ouabain led to a significant abbreviation of ventricular repolarization. This was more marked in dronedarone-pretreated hearts and resulted in an elevated incidence of VF. This may help to interpret the results of the PALLAS trial.
在 PALLAS 试验中观察到在使用决奈达隆时增加死亡率,人们讨论了决奈达隆与地高辛之间的相互作用可能是导致这种情况的原因。本研究的目的是在实验性全心模型中评估决奈达隆与地高辛联合使用可能产生的致心律失常作用。
26 只雌性兔接受了为期 6 周的慢性口服决奈达隆(50mg/kg/天)治疗。24 只兔子接受安慰剂治疗。通过快速心室起搏诱导心力衰竭。假手术组兔子接受右心室起搏导联,但未起搏。此后,心脏被分离并进行 Langendorff 灌注。单相动作电位和 12 导联心电图显示在应用哇巴因(0.1 和 0.2μM)后,在对照心脏和决奈达隆预处理心脏中,QT 间期、APD90、有效不应期和复极化后不应期呈剂量依赖性下降。急性应用哇巴因后,在未经处理的假手术心脏中,有 6 只(38 次)可通过程控心室刺激诱导心室颤动(VF),而在决奈达隆预处理的假手术心脏中,有 7 只(76 次)可诱导。在未经处理的衰竭心脏中,有 6 只(47 次)可诱导,而在决奈达隆预处理的衰竭心脏中,有 7 只(93 次)可诱导。
在这项研究中,哇巴因治疗导致慢性决奈达隆预处理的对照和衰竭心脏中的心室易损性增加。哇巴因导致心室复极明显缩短。在决奈达隆预处理的心脏中更为明显,导致 VF 的发生率升高。这可能有助于解释 PALLAS 试验的结果。